Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure.

Segarra A, Chacón P, Vilardell M, Piera LL

Nephron1 Jan 1996Cited by 8 (Europe PMC)

PMID8773342DOI10.1159/000189038PepBankPUB-08773342

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther
In men with chronic renal failure, testosterone and LH rose less after a gonadorelin stimulation test than in healthy controls, before lovastatin treatment.
In plain wordsIn men with kidney failure, hormone responses to a gonadorelin test were lower than in healthy men. Gonadorelin was a test tool.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseTestosterone and LH response to gonadorelin stimulation, patients versus controls
Study
n = 25
Comparator
Healthy matched controls
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
After stimulation with gonadorelin, they also showed a lower increase in testosterone and LH.
2 context sentences(design, population, supporting numbers)
Summary · context
Hormone studies were done prior to and after lovastatin treatment.
Summary · context
The values of these patients were compared with those of a matched healthy control group.
In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).
Report a problemFND-0877334201
02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneNon-randomized trialOther
In men with chronic renal failure, 12 months of lovastatin did not change the testosterone response to a gonadorelin stimulation test.
In plain wordsIn men with kidney failure, the lovastatin drug did not change hormone responses to a gonadorelin test. Gonadorelin was a test tool here.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeTestosterone response to gonadorelin stimulation after 12 months of lovastatin
Study
n = 25
Comparator
Before lovastatin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
After 12 months of lovastatin treatment, a significant decrease in the concentration of cholesterol, LDL C, VLDL C and apo B was observed, but neither the basal testosterone concentration nor the response to gonadorelin stimulation was modified.
2 context sentences(design, population, supporting numbers)
Summary · context
Hormone studies were done prior to and after lovastatin treatment.
Summary · context
The values of these patients were compared with those of a matched healthy control group.
In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).
Report a problemFND-0877334202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.